Sacrificing quality for quantity?: RE: Clinical Benefits and Cost-effectiveness of Allogeneic Red Blood Cell Transfusion in Severe Symptomatic Anemia A. M. Beliaev, R. J. Marshall, M. Gordon, W. Smith and J. A. Windsor

Vox Sanguinis

Volumn 103, Issue 4, 2012, Pages 360-361

  Shander, A ^a,b   Aregbeyen, O ^a   Caylan, M ^a  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ALLOGENEIC RED BLOOD CELL TRANSFUSION; ANEMIA; BLEEDING; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; MORTALITY; PEROPERATIVE COMPLICATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANEMIA; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; MALE;

EID: 84867849261     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01634.x     Document Type: Letter

References (4)

1. Klein HG: Brewing blood. Blood 2011; 118:5069-5070
2. Hendrickson JE, Hillyer CD: Noninfectiousserioushazards of transfusion. Anesth Analg 2009; 108:759-769 Review
3. Hofmann A, Farmer S, Shander A: Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 2011; 16(Suppl 3):3-11
4. Shander A, Hofmann A, Ozawa S, et al. : Activity based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50:753-765